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Surgery, University of Alberta, Edmonton, AB, CanadaWe recently demonstrated the generation of mouse induced
tissue-specific stem (iTS) cells through transient overexpres-
sion of reprogramming factors combined with tissue-specific
selection. Here we induced expandable tissue-specific progeni-
tor (iTP) cells from human pancreatic tissue through transient
expression of genes encoding the reprogramming factors
OCT4 (octamer-binding transcription factor 4), p53 small
hairpin RNA (shRNA), SOX2 (sex-determining region Y-box
2), KLF4 (Kruppel-like factor 4), L-MYC, and LIN28. Transfec-
tion of episomal plasmid vectors into human pancreatic tissue
efficiently generated iTP cells expressing genetic markers of
endoderm and pancreatic progenitors. The iTP cells differenti-
ated into insulin-producing cells more efficiently than human
induced pluripotent stem cells (iPSCs). iTP cells continued
to proliferate faster than pancreatic tissue cells until days
100–120 (passages 15–20). iTP cells subcutaneously inoculated
into immunodeficient mice did not form teratomas. Genomic
bisulfite nucleotide sequence analysis demonstrated that the
OCT4 and NANOG promoters remained partially methylated
in iTP cells. We compared the global gene expression profiles
of iPSCs, iTP cells, and pancreatic cells (islets >80%). Microar-
ray analyses revealed that the gene expression profiles of iTP
cells were similar, but not identical, to those of iPSCs but
different from those of pancreatic cells. The generation of
human iTP cells may have important implications for the
clinical application of stem/progenitor cells.Received 19 September 2018; accepted 17 January 2019;
https://doi.org/10.1016/j.omtm.2019.01.011.
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Adult tissue-specific stem/progenitor cells present in multiple adult
organs contribute to continuous tissue renewal or repair after injury
and may therefore represent an alternative therapy for numerous
diseases. Studies performed in vitro show that insulin (INS)-produc-
ing cells can be generated from adult pancreatic stem/progenitor
cells.1–3 The assessment of 83 human islet grafts transplanted using
the Edmonton Protocol from 1999 to 20044 shows a significant
positive correlation between the number of pancreatic progenitorMolecular Therapy: Methods &
This is an open access article under t(ductal-epithelial) cells transplanted and long-term metabolic suc-
cess, which was assessed using an intravenous glucose tolerance
test approximately 2 years after transplantation. Therefore, pancre-
atic duct/progenitor cells may serve as a new source of INS-
producing cells.
In contrast, it is difficult to isolate pancreatic “stem” cells, which have
unlimited self-renewal capacity. Although mouse pancreatic stem cell
lines were established using specific culture conditions,5,6 we could
isolate such cells only from young mice.7 Moreover, we were unable
to isolate pancreatic stem cells from human pancreatic tissue.8 The
unlimited availability of normal tissue-specific stem/progenitor cells
will undoubtedly contribute to a better understanding of stem cell
biology that is critical for effective organ repopulation in the applica-
tion of regenerative medicine. However, it is extremely difficult to
purify or expand tissue-specific stem/progenitor cells from native
tissues, because the population of such cells is very small.
Induced pluripotent stem cells (iPSCs), which are generated from
adult fibroblasts or other somatic cells, are similar to embryonic
stem cells (ESCs) in their morphology, gene expression pattern, epige-
netic status, and ability to differentiate into cells derived from the
three embryonic germ layers.9–15 iPSCs can be generated without
the genomic integration of genes encoding exogenous reprogram-
ming factors carried by plasmids,16–18 adenoviruses,19 or synthetic
RNAs.20 Moreover, the production of iPSCs without insertional
mutagenesis addresses a critical safety concern for their potential
use in regenerative medicine. However, the clinical application of
iPSCs is hampered by their ability to form teratomas and their limitedClinical Development Vol. 13 June 2019 ª 2019 The Author(s). 243
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
05
10
15
20
25
30
35
40
??5
??4
??3
??2
??1
D
iPS iTP
Pancreatic tissue GTE
C
iPSiTP
C
ol
on
y 
N
um
be
r
No factor4 factors
5th
3rd
2nd
1st
4th
iPSiTPiPSiTP
6 factors
C
op
ie
s p
er
 c
el
l (
lo
g 1
0)
iPS
07010804030201Pa-
d6
070605
iTP
1
2
-3
noisserpxe
1
X
DP
evitale
R
iPS
07010804030201Pa 070605
iTP
0
0
1
2
-4
-1
-2
BA Figure 1. Generation of Human iTP Cells from
Pancreatic Tissue
(A) The morphologies of human pancreatic tissue, GTE
cells, iPSCs, and iTP cells. Scale bar, 200 mm. (B)
Numbers of colonies of iTP and iPSCs. Episomal plasmid
vectors were transfected into human pancreatic
tissue, and the number of colonies was counted after
30–45 days. (C) qRT-PCR analysis of PDX1, a marker of
pancreatic stem/progenitor cells, in iTP and iPSCs. Eight
iTP clones and two iPS clones were evaluated for PDX1
expression using qRT-PCR. The data are expressed as
the PDX1-to-GAPDH ratio, with the ratio of pancreatic
tissue arbitrarily set to 1 (n = 5). Error bars represent the
SE. (D) Copy numbers of episomal plasmid vectors in iTP
and iPS clones. Pancreatic tissue 6 days after electro-
poration of plasmid vectors expressing six reprogram-
ming factors were analyzed (Pa-d6) as a positive control.
Molecular Therapy: Methods & Clinical Developmentpotential to generate pure populations of differentiated cell types
in vitro.
Recently, we focused on developing a method for generating induced
tissue-specific/progenitor stem (iTS/iTP) cells by transfecting cells
with a plasmid harboring cDNAs encoding octamer-binding tran-
scription factor (OCT) 3/4, sex-determining region Y-box (SOX) 2,
Kruppel-like factor 4 (KLF4), and MYC, followed by tissue-specific
selection.21–24 The iTS cells derived from mouse pancreas (iTS-P)
or liver (ITS-L), which express several genetic markers for endoderm
and pancreatic/hepatic progenitors, differentiated into INS-produc-
ing cells/hepatocytes more frequently than ESCs upon the induction
of differentiation. More important, the iTS-P/iTS-L cells were unable
to generate teratomas when subcutaneously transplanted into immu-
nodeficient mice. Moreover, evidence indicates that after the reprog-
ramming of mouse/human iPSCs, epigenetic memory is inherited
from the parental cells, and the iPSCs with epigenetic memory differ
from ESCs in their gene expression profiles, persistence of donor
cell gene expression, and ability to differentiate.25–30 Therefore, iTS
cells inherit numerous components of epigenetic memory from
pancreas/liver cells and acquire self-renewal potential.
Here we generated expandable iTP cells from human pancreatic tis-
sue using episomal plasmid vectors expressing OCT4, p53 small
hairpin RNA (shRNA), SOX2, KLF4, L-MYC, and LIN28.244 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019RESULTS
Generation of Human iTP Cells from
Pancreatic Tissue
We attempted to generate human iTP cells from
pancreatic tissue (>80% islets) by transfection of
episomal plasmid vectors expressing the re-
programming factors OCT4, SOX2, KLF4, and
MYC or OCT4, p53 shRNA, SOX2, KLF4,
L-MYC, and LIN28.17We generated 64 colonies
(Figure 1A) using the latter set of reprogram-
ming factors (Figure 1B). Of the 64 clones, 26showed an iPS-like morphology and generated teratomas (Table 1).
The other 38 clones exhibited an iTP-like morphology similar to
that of gut tube endodermal (GTE) cells. GTE cells were generated us-
ing a stepwise differentiation protocol that relied on intermediates
thought to be similar to the cell populations present in the developing
embryo.31,32 The latter 38 clones did not generate teratomas (Fig-
ure 1A; Table 1). Eight of the latter clones were evaluated for their
expression of pancreatic and duodenal homeobox factor (PDX) 1, a
marker of pancreatic stem/progenitor cells. All clones expressed
PDX1 mRNA (Figure 1C).
We next estimated the copy numbers of the episomal plasmid vectors
in these clones using a PCR primer pair to amplify the EBNA-1
sequence of Epstein-Barr virus.17 Approximately 100 copies of the
episomal plasmid vectors per cell were detected 6 days after transfec-
tion. In contrast, EBNA-1 DNA was undetectable in eight clones
tested at passage 10. One of two iPS clones contained two copies, indi-
cating chromosomal integration of the plasmid (Figure 1D). We used
clone iTP05 for subsequent experiments because it expressed the
highest levels of PDX1 mRNA.
Genes of Interest Expressed by Human iTP Cells
ESC marker genes expressed by iTP05 cells were detected using
RT-PCR assays. The levels of mRNAs encoding the pluripotency
markers such as OCT4, SOX2, and NANOG were significantly lower
Table 1. Teratoma Formation
Cell Type
Injected Cell
Number
Mice Bearing Teratoma/Total
Mice Injected Period (Days)
iPS 1  106 26/26 60
iTP 1  106 0/38 150
www.moleculartherapy.orgcompared with those of iPSCs (Figure 2A). We next investigated the
expression patterns of genes encoding endodermal markers. GTE
cells generated from iPSCs were used as a positive control. The
expression of endodermal marker genes such as forkhead box protein
a2 (FOXA2) and hepatocyte nuclear factors 1b, 4a, 6 (HNF1b, 4a, 6)
was detected in iTP05 cells (Figure 2B) in a pattern similar to that of
GTE cells, but not iPSCs. We next investigated the gene expression
patterns of pancreatic markers. Pancreatic tissues (>80% islets)
were used as a positive control. The expression of PDX1, PTF1A,
and CA2 was detected in iTP05 cells, and NEUROD, ILS1, and
NKX6.1 were expressed at lower levels (Figure 2C).Proliferation of Human iTP Cells
We previously found that human pancreatic progenitor cells (duct-
rich population) proliferate until day 30.8 Here we evaluated the
proliferation of human pancreatic tissue cells, iTP cells, and iPSCs.
Human pancreatic tissue cells (including pancreatic duct cells)
divided until day 30. iTP cells continued to divide faster than pancre-
atic tissue cells after day 30 without detectable changes in their
morphology or proliferation rate. However, iTP cells stopped dividing
on days 100–120 (passages 15–20). Therefore, the cells were “progen-
itor” cells rather than “stem” cells with unlimited self-renewal capa-
bility. The iPSCs proliferated after day 120 without detectable changes
in their morphology or proliferation rate (Figure 3A).Differentiation of Human iTP Cells into INS-Producing Cells
To evaluate the potential of iTP05 cells to differentiate, we applied a
stepwise differentiation protocol.31,32 iTP05 cells express endodermal
cell markers. Therefore, we included stages 4 and 5 of the induction
protocol of the stepwise differentiation protocol. iTP05 cells expressed
INS and its mRNA more efficiently than iPSCs (Figures 3B and 3C).
The INS-positive cells were C-PEPTIDE-positive, thus excluding the
possibility of INS uptake from the medium, and 15.4% ± 1.8% of
the differentiated cells were INS/C-PEPTIDE-double positive.
To determine the glucose sensitivity of the cells differentiated from
the iTP05 clone, we exposed them to low (2.8 mM) and then high
(20 mM) concentrations of glucose. The cells released approximately
2- to 3-fold higher amounts of human INS than an iPS-derived pop-
ulation in the presence of both glucose concentrations (Figure 3D).
The stimulation index of the cells differentiated from iTP05 cells
was higher compared with that of the iPSCs, although the difference
was not statistically significant (Figure 3E).
Differentiated iTP cells were transplanted into nude mice. The graft
contained approximately 15% INS-positive cells (Figure 3F, rightMoleculpanel). In contrast, Ki67-positive cells represented <5% of the en-
grafted cells (Figure 3F, left andmiddle panels), suggesting that differ-
entiated iTP cells infrequently proliferated after transplantation.
Bisulfite Genomic Sequencing of the Promoter Regions ofOCT4
and NANOG in iTP and iPS Cells
Bisulfite genomic nucleotide sequencing demonstrated that theOCT4
and NANOG promoters remained methylated in iTP cells but were
demethylated in iPSCs. In contrast, the PDX1 promoters were deme-
thylated in iTP cells (Figure 4). These results demonstrate that
methylation of these promoters in iTP cells differs from that in iPSCs.
Microarray Analysis
We performed microarray analysis to compare the global gene expres-
sion profiles of human iPSCs, iTP cells, andpancreatic tissue cells (islets
>80%). Of 54,613 genes, the levels of 7.6% differed by >2-fold between
iPSCs and iTP cells; the levels of 9.9% were >2-fold different between
pancreatic tissue and iTP cells; and the levels of 16.5% were >2-fold
different between iPSCs and pancreatic tissue (Figure 5A). These
data suggest that the expression pattern of iTP cells was similar to
that of iPSCsbut somewhat different from that of pancreatic tissue.Un-
supervised hierarchical clustering of gene expression profiles of iPSCs,
iTP cells, and pancreatic tissue showed that iTP cells clustered more
closely with iPSCs than pancreatic tissue cells (Figure 5B), although
the phenotypes of iTP cells markedly differed from those of iPSCs.
Restriction of the Developmental Potential of iTP Cells
To determine whether the developmental potential of human iTP
cells was restricted to pancreatic lineages, cultures were induced using
the conditions established to drive iPSCs toward hepatocytes,33 neu-
roectoderm,34 or mesoderm.33 Increased levels of mRNAs encoding
the liver markers ALBUMIN (ALB) or a1-AT (Figures 6A and 6B),
the mesodermal markers platelet/endothelial cell adhesion molecule
1 (PECAM1), or Mix1 homeobox-like 1 (MIXL1) (Figures 6C and
6D), as well as those of the neuroectodermal markers zinc-finger
protein of the cerebellum 1 (ZIC1) or SOX1 (Figures 6E and 6F),
were not detectable in the iTP cells, suggesting that iTP cells are
committed to tissue-specific differentiation.
Reproducible Generation of Human iTP Cells
We investigated the characteristics of human iTP cells derived from
each of five human donors to evaluate the reproducibility of generating
iTP cells. Thirty-eight clones that exhibited an iTP-like morphology
expressed PDX1 mRNA (Figure S2A). The five clones that expressed
the highest levels of PDX1 mRNA, iTP05, iTP11, iTP25, iTP36, and
iTP45, were selected for further analysis. PCR analysis did not detect
EBNA-1 DNA in any of the clones after passage 10 (Figure S2B).
We next used RT-PCR to detect the expression of genes that serve as
markers of ESCs, endodermal cells, or pancreatic cells. The levels of
mRNAs encoding pluripotency markers such as OCT4, SOX2, and
NANOG were significantly lower compared with those of iPSCs (Fig-
ure S3A). The pattern of expression of endodermal marker genes such
as FOXA2 and HNF1b, 4a, 6 (Figure S3B) was similar to that of GTEar Therapy: Methods & Clinical Development Vol. 13 June 2019 245
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Figure 2. qRT-PCR Analysis of Human iTP Cells for
Marker Genes of ESCs and Endodermal/Pancreatic
Cells
(A) qRT-PCR analysis of ESC marker genes in human
iTP05 cells. iPSCs served as a control. (B) qRT-PCR
analysis of endodermal cell marker genes in human iTP05
cells. GTE cells were used as a control. (C) qRT-PCR
analysis of pancreatic cell marker genes in human iTP05
cells. Pancreatic cells (islets >80%) were used as a
control. The data are expressed as the gene-to-GAPDH
ratio, with that of the control cells arbitrarily set to 1 (n = 4).
The error bars represent the SE. GT, GTE cells; iP, iPSCs;
iT, iTP05 cells; Pa, pancreatic cells (islets >80%).
Molecular Therapy: Methods & Clinical Developmentcells, but not iPSCs. Each clone expressed mRNAs encoding PDX1,
PTF1A, and CA2 and lower levels of mRNAs encoding NEUROD,
ILS1, and NKX6.1 (Figure S3C). These data suggest that it is possible
to reproducibly generate iTP cells.
DISCUSSION
Here we show that enforced transient expression of six reprogram-
ming factors in differentiated pancreatic cells induced the generation
of iTP cells with functional and molecular attributes corresponding to
their tissue-specific progenitor cells. Further, the iTP cells were
readily expanded in vitro. Although mouse pancreatic stem cells
have been identified,5–7 it is extremely difficult to isolate human
pancreatic stem cells capable of self-renewal.8 Therefore, the genera-
tion of human iTP cells using iPS cell technology may contribute to
the development of new treatments for diabetes.246 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019We show here that the self-renewal capacity of
human iTP cells was significantly higher than
that of normal pancreatic progenitor cells
(duct-rich population), although normal pancre-
atic progenitor cells and iTP cells have limited
self-renewal capacity (Figure 3A). In contrast,
we previously reported the generation of mouse
iTS-P cells with unlimited self-renewal capacity.6
The difference in the self-renewal capacity be-
tween human and mouse cells may be explained
by differences in epigenetic alterations during re-
programming. We previously generated mouse
iTS-P cells using four reprogramming factors
in our previous study.6 Here we generated
human iTP cells using six reprogramming fac-
tors. Similarly, mouse iPSCs are generated using
plasmids expressing four factors,16 whereas
human iPSCs are generated using plasmids
expressing six factors.17,18 Thus, epigenetic
changes during the reprograming of mouse cells
may be less complex than those during the
reprograming of human cells.
The difference in the self-renewal capacity be-
tween human and mouse cells may be furtherexplained by the differences in the conditions used to culture human
and mouse ESCs. Although the culture conditions for mouse ESCs
(culture media containing leukemia inhibitory factor) are suitable
for mouse pancreatic stem cells and iTS-P cells, it is unclear whether
those for human ESCs (culture media containing basic fibroblast
growth factor [bFGF]) are suitable for human pancreatic stem cells
and iTS-P cells. Thus, if we generate iTS-P cells from human pancre-
atic tissue, the cells may not maintain the undifferentiated phenotype
when cultured under unsuitable conditions.
The amount of INS secreted by iTP cells was higher compared with
that of iPSCs. However, the absolute value of the stimulation index
was quite low, suggesting that INS-producing cells generated from
iTP cells were unable to fully respond to fluctuations in glucose con-
centrations. To our knowledge, there is no established protocol for
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Figure 3. Proliferation of iTP Cells and Their
Differentiation into Insulin-Producing Cells
(A) Growth curves of iPSCs, iTP cells, and pancreatic
tissue cells. (B) Immunohistochemical analysis of INS-
producing cells (INS, C-PEPTIDE) derived from iTP05 cells
treated with the stepwise protocol. Scale bar, 100 mm. (C)
qRT-PCR analysis of INS expression in differentiated iTP05
cells. qRT-PCR analysis of differentiated cells derived from
iTP05 cells (passage 10) at stages 4–5, derived from iPSCs
at stages 1–5. Isolated islets (islets >80%) were used as a
positive control. Thedataare expressedas the INS:GAPDH
ratio, with that of the islets arbitrarily set to 100 (n = 4). Error
bars represent the SE. (D) INS release assay. Differentiated
cells derived from iTP05 cells (passage 10) using the stage
4–5 protocol and derived from iPSCs using the stage 1–5
protocol were treated with 2.8 and 20 mMD-glucose, and
the amount of INS released into the culture supernatant
was analyzed using an ELISA. Error bars represent the
SE. (E) The stimulation index shown in (D). Error bars
represent the SE. *p < 0.05. (F) Immunohistochemical
analysis of Ki67 expression (left panel, low magnification;
middle panel, high magnification [dotted square, left panel]
and INS expression (right panel, red cells) derived from
engrafted iTP05 cells in the graft. Scale bars, 100 mm.
www.moleculartherapy.orginducing the differentiation of pancreatic stem/progenitor cells into
INS-producing cells. When we transplanted differentiated iTP cells
into nude mice with diabetes, the mice did not become normoglyce-
mic. Establishing an efficient, reproducible protocol for generating
INS-producing cells is critically important for clinical applications.
We show here that human iTP cells differentiated into INS-producing
cells more efficiently than iPSCs and did not form teratomas. In strik-
ing contrast, ESCs/iPSCs may form teratomas, even after transplanta-
tion of differentiated cells derived from ESCs/iPSCs, because of
possible contamination with undifferentiated cells. The decreased po-
tential for teratoma formation illustrates an advantage of using iTP
cells for regenerative medicine compared with ESCs/iPSCs. Further,
bisulfite nucleotide sequence analysis of genomic DNA performed
here clearly demonstrates that the promoters of OCT4 and NANOG
remained methylated in iTP cells, whereas the promoters were deme-
thylated in iPSCs. Moreover, qRT-PCR assays detected low levels of
OCT4 orNANOGmRNA. These results demonstrate that the methyl-
ation of these promoters in iTP cells was not similar to that of iPSCs.Molecular Therapy: Methods &The global gene expression profiles of iPSCs, iTP
cells, and pancreatic tissue cells show that iTP
cells markedly differed from iPS and pancreatic
cells. Unsupervised hierarchical clustering of
gene expressionprofiles shows that iTP cells clus-
tered more closely with iPSCs than pancreatic
cells (Figure 5). Thus, the expression profile and
genomic methylation status of iTP cells clearly
differed from those of iPSCs and pancreatic islets.
In conclusion, we generated human iTP cells
from pancreatic cells using episomal plasmidvectors expressing six reprogramming factors. Another group
recently generated expandable induced tissue-specific stem/progeni-
tor cells with characteristics similar to those of the iTS/iTP cells
studied here, through the transient expression of YAP/TAZ,35 as
well as with endodermal stem/progenitor cells using defined small
molecules.36 iTS/iTP cells provide advantages over iPSCs. For
example, they are easier to generate, differentiate efficiently, and do
not form teratomas. The regeneration of pancreatic-b cells from
stem and progenitor cells is an attractive method for restoring the
islet cell mass. We believe that our present findings provide compel-
ling evidence that our protocol for inducing tissue-specific stem/
progenitor cells using reprogramming factors will advance the field
of regenerative medicine.
MATERIALS AND METHODS
Generation of iPSCs and iTP Cells from Human Pancreatic Cells
Pancreatic cells (>80% islets) from human neurological determination
of death (NDD) donors (woman, age 20–40 years, 5 cases) were iso-
lated at the University of Alberta after donor family and human ethicsClinical Development Vol. 13 June 2019 247
Figure 4. Bisulfite Sequence Analysis of Genomic
DNA
Bisulfite sequence analysis of the OCT4, NANOG, and
PDX1 promoter regions in iTP05 cells and iPSCs. Open
and closed circles indicate unmethylated and methylated
CpG dinucleotides, respectively.
Molecular Therapy: Methods & Clinical Developmentresearch consents were obtained, as previously described.37 Cells were
shipped to Japan and maintained in DMEM (Life Technologies,
Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Thermo
Scientific, Kanagawa, Japan) and 0.5% penicillin (Sigma-Aldrich, St.
Louis, MO, USA). Plasmid vectors expressing the reprogramming
factors OCT4, SOX2, KLF4, MYC or OCT4, p53 shRNA, SOX2,
KLF4, L-MYC, and LIN2817 were electroporated into 6 105 pancre-
atic cells using a Microporator (Invitrogen) with a 100-mL kit accord-
ing to the manufacturer’s instructions. For pancreatic cells, conditions
were 1,650V, 10ms, and three pulses. The cells were trypsinized 7 days
after transfection, and 1 105 cells were replated onto 100-mm dishes
covered with a mouse embryo fibroblast (MEF) feeder layer. The cul-
ture medium was replaced the next day with primate ESC medium
containing bFGF (Repro CELL, Kanagawa, Japan). The colonies
were counted 30–45 days after plating, and colonies similar to human
ESCs or GTE cells were selected for further cultivation and evaluation
(Figure S1A).
Cell Culture
iPS and iTP cells (induced cells described above) were maintained on
an MEF feeder layer in DMEM-F12 (Sigma-Aldrich), 2 mM L-gluta-
mine (Nacalai Tesque, Kyoto, Japan), 1:100 dilution of nonessential
amino acids (Life Technologies), 0.1 mM b-mercaptoethanol
(Sigma-Aldrich), 5 ng/mL bFGF (Repro CELL), and penicillin/
streptomycin (Sigma-Aldrich). For passaging, iPS/iTP colonies were
dissociated with Dissociation Solution for human ESCs/iPSCs (Riken
CDB, Kobe, Japan) and split at ratios between 1:3 and 1:6.
Teratoma Formation/Tumorigenicity Assay
All mouse studies were approved by the Review Committee of the Uni-
versity of the Ryukyus. Eight-week-old non-obese diabetic/severe com-
bined immunodeficiency (NOD/SCID) mice (CLEA, Tokyo, Japan)
were used for teratoma formation studies. iPS/iTP cells (1  106)
were inoculated into the humerus and thigh of NOD/SCID mice.
qRT-PCR
Total RNA was extracted from cells using an RNeasy Mini Kit
(QIAGEN, Tokyo, Japan). After quantifying the RNA by spectropho-
tometry, 2.5 mg of RNA was heated at 85C for 3 min and then248 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019reverse-transcribed in a 25-mL solution contain-
ing 200 U of Superscript II RNase H-RT
(Invitrogen), 50 ng of random hexamers (Invi-
trogen), 160 mmol/L dNTP, and 10 nmol/L
dithiothreitol. The reactions were incubated
for 10 min at 25C, 60 min at 42C, and
10 min at 95C. mRNAs were quantified usinga TaqMan real-time PCR system according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA, USA). PCR was
performed for 40 cycles, including 2 min at 50C and 10 min at
95C as initial steps. In each cycle, denaturation was performed for
15 s at 95C, and annealing/extension was performed for 1 min at
60C. PCR was performed in a 20-mL solution containing cDNAs
synthesized from 1.11 ng of total RNA. For each sample, the levels
of mRNAs were normalized by dividing by them by the levels of
GAPDH. Primers for human genes encoding OCT4, SOX2, KLF4,
NANOG, LIN28, TERT, NODAL, REX, FOXA2, SOX17, HNF1b,
HNF4a, HNF6, HLXB9, SOX9, CD133, PDX1, PTF1a, NGN3,
NEUROD, ISL1, NKX6.1, CA2, GLP1R, INS, ALB, a1-AT, PECAM1,
MIXL1, ZIC1, SOX1, and GAPDH were purchased from Assays-
on-Demand Gene Expression Products (Applied Biosystems). A
PCR primer pair representing the EBNA-1 sequence derived from
Epstein-Barr virus17 was used to estimate the copy numbers of
episomal plasmid vectors.
Cell Induction and Differentiation
Directed differentiation into INS-producing cells was conducted as
described previously,31,32 with minor modifications. iPSCs (pas-
sage 10) and iTP cells (passage 10) were used in this experiment.
In stage 1, cells were treated with 25 ng/mL Wnt3a and
100 ng/mL activin A (R&D Systems, Minneapolis, MN, USA) in
RPMI (Invitrogen) for 1 day, followed by treatment with
100 ng/mL activin A in RPMI + 0.2% FBS for 2 days. In stage 2,
the cells were treated with 50 ng/mL FGF10 (R&D Systems) and
0.25 mM 3-keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)
(KAAD)-cyclopamine (Toronto Research Chemicals, Toronto,
Canada) in RPMI + 2% FBS for 3 days. In stage 3, the cells were
treated with 50 ng/mL FGF10, 0.25 mM KAAD-cyclopamine, and
2 mM all-trans retinoic acid (Sigma-Aldrich) in DMEM + 1% (v/v)
B27 supplement (Invitrogen) for 3 days. In stage 4, the cells were
treated with 1 mM N-[N-(3, 5-difluorophenacetyl)-1-alanyl]-S-
phenylglycinet-butylester (DAPT; Sigma-Aldrich) and 50 ng/mL
exendin-4 (Sigma-Aldrich) in DMEM + 1% (v/v) B27 supplement
for 3 days. In stage 5, the cells were treated with 50 ng/mL exen-
din-4, 50 ng/mL IGF-1 (Sigma-Aldrich), and 50 ng/mL hepatocyte
growth factor (R&D Systems) in Connaught Medical Research
Figure 5. Microarray Analysis
(A) Global gene expression patterns were compared between iPSCs and iTP cells, between pancreatic tissue cells and iTP cells, and between iPSCs and pancreatic tissue
cells using a Transcriptome Analysis Console (Affymetrix). The gray area indicates genes expressed at levels <2-fold different between the two samples. (B) Unsupervised
hierarchical clustering of gene expression profiles of iPSCs, iTP cells, and pancreatic tissue cells. Each column represents one biological sample.
www.moleculartherapy.orgLaboratories medium (CMRL; Invitrogen) + 1% (v/v) B27 supple-
ment for 3–6 days (Figure S1B).
Immunohistochemistry
The cells were fixed with 4% paraformaldehyde in PBS. After
blocking with 20% AquaBlock (EastCoast Bio, North Berwick,
ME, USA) for 30 min at room temperature, the cells were incu-
bated overnight at 4C with a guinea pig anti-INS antibody
(1:100; Abcam, Tokyo, Japan) or rabbit anti-C-PEPTIDE antibody
(1:200; Cell Signaling Technology, Danvers, MA, USA) and then
for 1 h at room temperature with fluorescein isothiocyanate
(FITC) or Alexa Fluor 647-conjugated anti-guinea pig immuno-
globulin G (IgG) (FITC, 1:250 [Abcam] and Alexa Fluor 647,
1:250 [Cell Signaling Technology]), or Alexa Fluor 647-conjugated
anti-rabbit IgG (1:250; Cell Signaling Technology). The cells wereMoleculmounted on slides using VECTASHIELD Antifade Mounting
Medium with DAPI (Vector Laboratories, Peterborough, UK).
The percentage of INS/C-PEPTIDE-positive cells was calculated
based on the ratio of immunostaining-positive cells/DAPI-positive
cells in 10 visual fields.
To identify proliferating cells, we used immunohistochemistry (IHC)
to detect Ki67 in the nuclei of cells in the G1, S, G2, and M phases of
the cell cycle. For this purpose, we used the Histofine Simple Stain
MAX PO (R) kit (Nichire Biosciences, Tokyo, Japan) with an anti-
Ki67 antibody (ab 15580) (Abcam, Cambridge, UK).
Transplantation of Differentiated iTP Cells
Differentiated iTP cells were transplanted into the renal subcapsular
space of the left kidneys of nudemice. One week after transplantation,ar Therapy: Methods & Clinical Development Vol. 13 June 2019 249
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Figure 6. Restriction of the Developmental Potential
of iTP Cells
(A) qRT-PCR analysis of ALB expression in undiffer-
entiated and differentiated iTP cells. (B) qRT-PCR
analysis of a1-AT in undifferentiated and differentiated
iTP cells. (C and D) qRT-PCR analysis of mesodermal
genes PECAM1 (C) and MIXL1 (D) in undifferentiated
and differentiated iTP cells. (E and F) qRT-PCR analysis
of the expression of the neuroectodermal genes ZIC1
(E) and SOX1 (F) in undifferentiated and differentiated
iTP cells. iPSCs and the differentiated cells derived
from iPSCs were used as controls. *p < 0.05 compared
with other cells. The data are expressed as the gene-
to-GAPDH ratio, with that of the differentiated cells
from iPSCs arbitrarily set to 1 (n = 4). Error bars
represent the SE.
Molecular Therapy: Methods & Clinical Developmentthe grafts were harvested and subjected to IHC using antibodies
against Ki67 and INS. Studies using mice were approved by the Insti-
tutional Animal Care and Use Committee of the University of the
Ryukyus.
INS Release Assay
INS release was measured by incubating the cells in Functionality/
Viability Medium CMRL1066 (Mediatech). The cells were washed
three times in PBS and incubated in the solution (Functionality/
Viability Medium CMRL1066) with 2.8 mM D-glucose six times for
20 min each (total 2 h) to wash them. The cells were then incubated
in the solution with 2.8 mMD-glucose for 2 h and then in the solution250 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019with 20 mM D-glucose for 2 h. The INS levels
in the culture supernatants were measured using
an Ultrasensitive Human Insulin ELISA kit
(Mercodia).
Bisulfite Genomic Sequencing
Bisulfite treatment was performed using the
CpGenome Turbo Bisulfite Modification Kit
(Merck Millipore) according to the manufac-
turer’s recommendations. The PCR primers
are listed in Table S1. Amplified products
were cloned using a Mighty TA-Cloning Kit
(Takara Bio, Shiga, Japan). Ten randomly
selected clones were sequenced with the
M13 forward and reverse primers for each
gene.
Microarrays
The total RNA from ESCs, iTS-P cells, or islets
was labeled with biotin. Samples were hybrid-
ized using a GeneChip 30IVT PLUS Reagent
Kit (Affymetrix, Tokyo, Japan) and a GeneChip
Hybridization, Wash and Stain Kit (Affymetrix)
according to the manufacturer’s protocol.Arrays were scanned using a GeneChip Scanner 3000 7G (Affyme-
trix). Data were analyzed using the Transcriptome Analysis Console
(Affymetrix).
Statistical Analysis
The data are expressed as the mean ± SE. To compare the data among
groups, we used a repeated-measures ANOVA test. Two groups were
compared using the Student’s t test. The differences between each
group were considered significant if the p value was <0.05.
All methods were performed in accordance with the relevant guide-
lines and regulations.
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